Item 5.02(b). Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 25, 2022, Eric Cheng notified Medicus Sciences Acquisition Corp. (the
"Company") that he was resigning as Chief Business Officer of the Company
effective immediately. Mr. Cheng's resignation was not the result of any
disagreement with the Company. On March 25, 2022, the Board of Directors of the
Company appointed Neil Puri as Chief Business Officer of the Company, effective
immediately.
Dr. Puri joined Altium Capital Management LP in August 2021 as an Analyst
focused on investments within the healthcare sector. Dr. Puri was previously a
Senior Analyst at Alera Partners, a healthcare-dedicated investment fund from
April 2021 to August 2021. He began his Wall Street career as a Sr. Associate in
Biotechnology Equity Research at BMO Capital Markets from 2018 to 2019, and has
had other sell-side positions focused on biotechnology including Equity Research
at SVB Leerink from 2019 to 2022 and Investment Banking at Jefferies from 2020
to 2021. Before entering finance, Dr. Puri obtained his board certification in
Internal Medicine, and has practiced clinical medicine following completion of
his Internal Medicine Residency at Thomas Jefferson University Hospital in 2012.
Dr. Puri earned his B.S. in Economics from Duke University, then attended
Rutgers - Robert Wood Johnson Medical School where he earned his M.D. In
addition, he earned his M.B.A. from the University of Chicago - Booth School of
Business.
There are no arrangements or understandings between Dr. Puri and any other
person pursuant to which any of Dr. Puri was selected as an officer of the
Company. There are no family relationships between Dr. Puri and any of the
Company' s other directors or executive officers.
There are no transactions between the Company and Dr. Puri that are subject to
disclosure under Item 404(a) of Regulation S-K.
© Edgar Online, source Glimpses